文献速递姑息放疗与转移瘤中枢神经肿瘤放疗

识别临近生命终末期仍可从姑息放疗中获益的恶性脊髓压迫(MSCC)患者

Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.
PubMed 文献 · Radiat Oncol · 2022-08-17

研究回顾性分析545例放疗后≤2个月死亡的MSCC患者,开发新评分以识别仍可能从姑息放疗中获益(运动功能改善或维持行走)者。基于骨髓瘤/淋巴瘤、运动缺陷发展时间>14天和放疗前行走状态三个因素,将患者分为0、1、2-3分三组,治疗成功率分别为4%、15%、39%,放疗后行走率分别为4%、43%、86%(p<0.0001)。

要点

  • 新评分基于骨髓瘤/淋巴瘤、运动缺陷发展>14天和放疗前行走状态三个因素。
  • 评分0、1、2-3分组的治疗成功率分别为4%、15%、39%(p<0.0001)。
  • 评分0、1、2-3分组放疗后行走率分别为4%、43%、86%(p<0.0001)。

核心结论

  • 该评分有助于识别临近生命终末期但似乎仍可从姑息放疗中获益(运动功能改善或维持行走)的MSCC患者。

研究设计与样本

  • 回顾性评估545例放疗后≤2个月内死亡的MSCC患者的治疗前因素及放疗方案,分析治疗成功(运动功能改善或无需辅助维持行走)和放疗后行走状态。

主要发现

  • 多因素分析显示,骨髓瘤/淋巴瘤、运动缺陷发展时间>14天和放疗前行走状态与治疗成功及放疗后行走状态均显著相关,1-2个椎体受累仅与治疗成功显著相关。
  • 单因素分析显示,1×8 Gy和5×4 Gy方案不劣于5×5 Gy及长疗程方案。
  • 基于三个因素设计的0、1、2-3分三组治疗成功率分别为4%、15%、39%(p<0.0001),放疗后行走率分别为4%、43%、86%(p<0.0001)。

关键数值与推荐

  • 评分因素:骨髓瘤/淋巴瘤(1分)、运动缺陷发展时间>14天(1分)、放疗前可行走(1分);结局较差计0分,较好计1分。
  • 0分、1分、2-3分组的治疗成功率分别为4%、15%、39%(p<0.0001)。
  • 0分、1分、2-3分组的放疗后行走率分别为4%、43%、86%(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A previous score predicted death ≤ 2 months following radiotherapy for MSCC. For patients with a high probability of early death, best supportive care was recommended. However, some of these patients may benefit from radiotherapy regarding preservation or improvement of motor function. To identify these patients, an additional score was developed. METHODS: Pre-treatment factors plus radiotherapy regimen were retrospectively evaluated for successful treatment (improved motor function or remaining ambulatory without aid) and post-treatment ambulatory status in 545 patients who died ≤ 2 months. Factors included age, interval from tumor diagnosis until MSCC, visceral metastases, further bone metastases, primary tumor type, sex, time developing motor deficits, pre-treatment ambulatory status, and number of affected vertebrae. Factors significant on both multivariable analyses were included in the score (worse outcomes 0 points, better outcomes 1 point). RESULTS: On multivariable analyses, myeloma/lymphoma, time developing motor deficits > 14 days, and pre-treatment ambulatory status were significantly associated with both successful treatment and ambulatory status, affection of 1-2 vertebrae with successful treatment only. On univariable analyses, 1 × 8 and 5 × 4 Gy were not inferior to 5 × 5 Gy and longer-course regimens. Considering the three factors significant for both endpoints, three groups were designed (0, 1, 2-3 points) with treatment success rates of 4%, 15% and 39%, respectively (p < 0.0001), and post-treatment ambulatory rates of 4%, 43% and 86%, respectively (p < 0.0001). CONCLUSION: This score helps identify patients with MSCC who appear to benefit from palliative radiotherapy in terms of improved motor function or remaining ambulatory in spite of being near end of life.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rades D, Segedin B, Schild SE, et al. Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy. Radiat Oncol. 2022. PMID: 35978340. doi:10.1186/s13014-022-02117-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。